<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00478374</url>
  </required_header>
  <id_info>
    <org_study_id>JFD-12581</org_study_id>
    <nct_id>NCT00478374</nct_id>
  </id_info>
  <brief_title>Sorafenib With TACE to Treat Hepatocellular Carcinoma</brief_title>
  <acronym>S-TACE</acronym>
  <official_title>Transarterial Chemoembolisation With Doxorubicin in Combination With Systemic Administration of Sorafenib for Patients With Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Bern</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the feasibility to combine sorafenib with&#xD;
      transarterial chemoembolisation in patients suffering from hepatocellular carcinoma.The&#xD;
      hypothesis is that sorafenib may prevent the development and growth of tumoral lesions not&#xD;
      treated by chemoembolisation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety and tolerability of the administration of sorafenib in patients with hepatocellular carcinoma treated with TACE by determining the MTD.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>tumor volumetry</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in the blood concentration of tumor marker AFP</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Sorafenib 400mg bid</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transarterial chemoembolisation with doxorubicin</intervention_name>
    <description>Transarterial chemoembolisation (TACE)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with inoperable HCC, who are candidates for transarterial chemoembolization&#xD;
             (TACE).&#xD;
&#xD;
          -  Diagnosis of hepatocellular carcinoma based on the EASL's criteria (1).&#xD;
&#xD;
          -  Child-Pugh score &lt; 10 (Child A or B),&#xD;
&#xD;
          -  Life expectancy superior to 12 weeks at the pre-treatment evaluation.&#xD;
&#xD;
          -  Local therapies have been interrupted for at least 4 weeks&#xD;
&#xD;
          -  Written informed consent signed&#xD;
&#xD;
          -  Age &gt;= 18&#xD;
&#xD;
          -  Performance status ECOG 0-1&#xD;
&#xD;
          -  Normal organ and marrow function defined as:&#xD;
&#xD;
               -  Haematopoietic: absolute neutrophil count &gt;1,500/mm3, platelet count &gt;&#xD;
                  60,000/mm3, haemoglobin &gt; 9g/dL&#xD;
&#xD;
               -  INR &lt; 1.5 ULN and PTT within normal limits&#xD;
&#xD;
               -  Hepatic: AST or ALT &lt; 5 x ULN&#xD;
&#xD;
               -  Renal: creatinine &lt; 1.5 x ULN&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test performed&#xD;
             within 7 days prior to the start of treatment&#xD;
&#xD;
          -  Women of childbearing potential and men must agree to use adequate birth contraception&#xD;
             (must be double and methods recorded) prior to study entry and for the duration of the&#xD;
             study participation. For both men and women, these adequate birth control measures&#xD;
             must be used for at least 3 months after the last administration of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active heart disease is defined as congestive heart failure &gt;NYHA (New York Heart&#xD;
             Association) class 2; active coronary artery disease (myocardial infarction more than&#xD;
             6 months prior to study entry is allowed); cardiac arrhythmias requiring&#xD;
             anti-arrhythmic therapy (beta-blockers or digoxin are permitted) or uncontrolled&#xD;
             hypertension.&#xD;
&#xD;
               -  Congestive heart failure, serious cardiac arrhythmia, active coronary artery&#xD;
                  disease.&#xD;
&#xD;
               -  Thrombotic or embolic events within the past 6 months such as a cerebrovascular&#xD;
                  accident (including transient ischemic attacks), pulmonary embolism.&#xD;
&#xD;
               -  Uncontrolled intercurrent illness including, but not limited to, ongoing or&#xD;
                  active infection.&#xD;
&#xD;
               -  Psychiatric illness/social situations that would limit compliance with study&#xD;
                  requirements.&#xD;
&#xD;
               -  Patients with evidence of active infection will become eligible for&#xD;
                  reconsideration 7 days after completing antibiotic therapy.&#xD;
&#xD;
               -  HIV-positive patients receiving combination anti-retroviral therapy are excluded&#xD;
                  from the study because of possible pharmacokinetic interactions with sorafenib.&#xD;
&#xD;
               -  Patients who have been treated with sorafenib.&#xD;
&#xD;
               -  Cerebral metastasis.&#xD;
&#xD;
               -  Child-Pugh score C.&#xD;
&#xD;
               -  Hypertension defined as systolic blood pressure greater than 150 mmHg or&#xD;
                  diastolic pressure greater than 90 mmHg despite optimal medical management.&#xD;
&#xD;
               -  Proteinuria defined as a 24-hour urine protein excretion greater than 1000 mg.&#xD;
                  Urine dipstick proteinuria of 1+ or greater will require a 24-hour urine to&#xD;
                  determine eligibility for enrolment.&#xD;
&#xD;
               -  Therapeutic anticoagulation with coumarin, heparins, or heparinoids.&#xD;
&#xD;
               -  Serious non-healing wounds (including wounds healing by secondary intention),&#xD;
                  acute or non-healing ulcers, or bone fractures within 3 months of fracture.&#xD;
&#xD;
               -  Evidence of bleeding diathesis.&#xD;
&#xD;
               -  Impairment of swallowing that would preclude administration of sorafenib.&#xD;
&#xD;
               -  History of haemoptysis or surgery within the past 28 days.&#xD;
&#xD;
               -  Organ allograft.&#xD;
&#xD;
               -  Pregnant or breastfeeding patients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Candinas</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inselspital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Markus Borner</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inselspital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Fran√ßois J Dufour, MD</last_name>
    <role>Study Director</role>
    <affiliation>Inselspital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Dufour JF, Hoppe H, Heim MH, Helbling B, Maurhofer O, Szucs-Farkas Z, Kickuth R, Borner M, Candinas D, Saar B. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist. 2010;15(11):1198-204. doi: 10.1634/theoncologist.2010-0180. Epub 2010 Oct 29.</citation>
    <PMID>21036880</PMID>
  </results_reference>
  <verification_date>November 2010</verification_date>
  <study_first_submitted>May 23, 2007</study_first_submitted>
  <study_first_submitted_qc>May 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2007</study_first_posted>
  <last_update_submitted>November 1, 2010</last_update_submitted>
  <last_update_submitted_qc>November 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>J-F DUFOUR</name_title>
    <organization>University of Bern</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

